Specifically, pharmacological inhibition of mitochondrial fission could effectively alleviate CF activation in vitro, which also mitigated the concomitant TGF-β1-induced mtROS release and metabolic switch in activated CF. The gene discussed is TGFB1; the disease is cystic fibrosis.